Congress might provide a do-over for a drug firm that inadvertently missed filing for a patent extension by a day or two, and in so doing spare the prominent law firm WilmerHale a possible malpractice payout [Andrew Pollack, New York Times]

Filed under: lawyers, patent law, politics